A phase II study of adjuvant XXXX plus @entity1205 followed by concurrent chemoradation in resected pancreaticobiliary carcinoma.

@entity1 @entity788 @entity137 @entity55 @entity5 @entity1205 @entity3907 @entity1349 @entity204 @entity136 @entity1125 @entity1487
OBJECTIVES: Adjuvant @entity136 with or without chemoradiation is a standard therapeutic option for @entity1 with resected @entity788 . The feasibility and @entity137 of @entity136 with @entity1205 before and after @entity1487 ( @entity1487 )-based chemoradiation in the adjuvant pancreatic and @entity5 setting were investigated. METHODS: After a curative-intent resection, eligible @entity1 with @entity5 were treated with two cycles of @entity136 and @entity1205 followed by @entity1487 -based chemoradiation. Four weeks after completing chemoradiation, two cycles of @entity136 and @entity1205 were administered. The primary endpoint was the incidence of severe @entity137 . Secondary endpoints included disease-free survival (DFS) and @entity1349 ( @entity1349 ). RESULTS: Fifty @entity1 with @entity5 were enrolled. Twenty-nine @entity1 had @entity788 whereas 21 @entity1 had biliary tract or @entity5 . There was one @entity204 as a result of @entity55 , and 15% of @entity1 experienced grade 3 or greater non-haematological @entity137 . The median DFS and @entity1349 for @entity1 with @entity788 were 9.6 and 17 months, respectively, and for those with resected @entity1125 were 12 and 23 months, respectively. CONCLUSIONS: This combination of @entity136 and @entity1205 with chemoradiation is feasible and tolerable in the adjuvant setting. Future studies utilizing a different @entity136 / @entity3907 combination and schedule may be appropriate in the adjuvant treatment of both @entity788 and @entity5 .
